AI Article Synopsis
- A clinical trial assessed the effectiveness and safety of I-labeled metuximab in combination with transcatheter arterial chemoembolization (TACE) for treating patients with unresectable hepatocellular carcinoma.
- Results showed that patients receiving TACE along with I-metuximab experienced a median time to tumor recurrence of 6 months compared to 3 months for those receiving TACE alone.
- Additionally, the combined treatment led to a median overall survival of 28 months versus 19 months for TACE alone, demonstrating better outcomes and good patient tolerance for the new treatment.
Article Abstract
This prospective nonrandomized, multicenter clinical trial was performed to investigate the efficacy and safety of I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. The median time to tumor recurrence was 6 mo in the TACE + I-metuximab group ( = 160) and 3 mo in the TACE group ( = 160) (hazard ratio, 0.55; 95% CI, 0.43-0.70; < 0.001). The median overall survival was 28 mo in the TACE + I-metuximab group and 19 mo in the TACE group (hazard ratio, 0.62; 95% CI, 0.47-0.82; = 0.001). TACE + I-metuximab showed a greater antirecurrence benefit, significantly improved the 5-y survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973296 | PMC |
| http://dx.doi.org/10.2967/jnumed.121.262136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!